In recent years, cutting-edge regenerative medicine technologies from abroad have garnered widespread attention among China’s affluent population, as their clinical applications have matured. However, language barriers, uncertainty regarding the procedures for accessing cross-border medical services, and the difficulty of identifying reliable overseas medical institutions have, for many years, prevented many affluent Chinese with health needs from seeking such care.
JES Biotech, which has been deeply rooted in the field of regenerative medicine in Japan and China for many years and has leveraged the mature clinical systems of the SENSHIN Tokyo Future Medical Center, has recently entered into a strategic partnership with JD Health and has been officially designated as the point of contact for high-end clients of the Lang Jianwei Cell Therapy Hospital—a subsidiary of JD Health—to receive regenerative medicine services in Japan.Through this partnership, a clear, transparent, and safe pathway has been established for the first time, enabling Chinese clients to receive high-quality regenerative medicine services in Japan.
01 Witness a Historic Moment
Jiesheng Life Sciences attended the opening ceremony for the Lang Jianwei Cell Therapy Hospital.
On May 15, 2026, the JD Health Lang Jianwei Cell Therapy Hospital—JD Health’s first hospital specializing in cell therapy—officially opened in the Beidaihe New District of Qinhuangdao City, Hebei Province, marking the completion of a major strategic upgrade for JD Health in the field of regenerative medicine.
Mr. Cai Shitian, Representative Director of JES Life Technology Co., Ltd., and Dr. Richard Senshin, Director of the Tokyo Future Medical Center, attended the opening ceremony as key strategic partners of the Lang Jianwei Cell Therapy Hospital, a subsidiary of JD Health.Both witnessed firsthand how JD Health has made a comprehensive transition in the field of regenerative medicine—from strategic planning and talent acquisition to actual operations and clinical implementation—marking a significant leap from a “blueprint on paper” to a “tangible organization.”
Lang Jianwei Cell Therapy Hospital is understood to be not merely a single medical institution, but a comprehensive platform that integrates a medical facility, a cell research laboratory that meets GMP standards, and a translational research center.
当病院は、個別化精密医療、AI支援型健康管理、ハイエンドの健康・ウェルネス・アンチエイジングなどの医療サービス分野を有し、「保管・治療・健康・ウェルネス」の全チェーンを網羅する再生医療サービスシステムを構築しています。
The official opening of the Lang Jianwei Cell Therapy Hospital is not only a significant tangible achievement that demonstrates the deep expertise JD Health has cultivated in the field of regenerative medicine, but it also aligns precisely with the policy direction toward the standardized development of the national cell therapy industry. It can be said to press the “fast-forward button” for the clinical application and widespread adoption of cell technology in China.
At the same time, the establishment and operation of this hospital provided a central physical platform that allowed Jiesheng Life Sciences to fully leverage its dual roles as an “official service window to Japan” and an “academic and technical strategic partner,” thereby laying a solid foundation for the subsequent implementation of high-end cross-border medical services and Sino-Japanese joint research and development in regenerative medicine.
02 A Powerful Alliance
Jiesheng Life Sciences and JD Health have signed a strategic cooperation agreement.
At the announcement ceremony, Jiesheng Life Technology Co., Ltd.—the official designated point of contact and core technology partner for JD Health Lang Jianwei Hospital’s regenerative medicine services for high-end clients in Japan—signed strategic cooperation agreements with JD Health Management Services Co., Ltd.,Lang Jianwei Cell Therapy Hospital Co., Ltd., Hainan Special Economic Zone JD Health Comprehensive Clinic Co., Ltd., and Daohe Future (Beijing) International Health Technology Co., Ltd. Through the integration of resources and the synergy of their complementary strengths, they will jointly pioneer a new future of collaborative development in the vast healthcare industry.
This strategic partnership is viewed as a significant achievement resulting from months of dedicated collaboration, close coordination, and joint efforts between Jiesheng Life Sciences and JD Health.It represents a clear partnership between the two companies, focused on the demand for high-end medical services in line with development trends in the regenerative medicine industry.
この提携における最も注目すべき点の1つは、今回のパートナーシップにおいて、Jiesheng Life Scienceが、JD Health傘下のLangjianwei Cell Therapy Hospitalのハイエンド顧客が日本で再生医療サービスを受けるための公式窓口として正式に指定されたことである。
将来を見据え、J&SはSENSHIN東京未来医療センターで培ってきた専門知識とサービスシステムを活用し、朗建威病院の富裕層顧客に対し、中国での初期計画調整から日本での治療実施、中国帰国後の長期的な健康管理とフォローアップまで、日本での再生医療に関する包括的なサービスを提供し、完全なサービスループを構築していく予定です。
In other words, JES serves as JD Health’s point of contact in Japan, while also acting as a bridge to ensure the precise matching of cutting-edge regenerative medicine resources between China and Japan.
In terms of scientific research collaboration, building on this partnership,Senshin Tokyo Future Medical Center, a subsidiary of J&S Life Sciences, will continue to leverage the expertise of Chinese and Japanese specialists to foster close collaboration with JD Health in areas such as academic exchange and clinical data sharing, and will jointly promote active exchange and technological advancement in the cell therapy industries of China and Japan.
In addition to its core business of regenerative medicine services, Jieshi Life Science also offers professional-grade anti-aging products and health food series that meet the standards of specialized hospitals.Going forward, the company plans to leverage JD.com’s robust e-commerce and logistics network to expand into the cross-border e-commerce and health and wellness consumer goods markets, helping more consumers easily access high-quality anti-aging products and achieve healthier bodies and skin.
From Tokyo to Beidaihe, J&S Life Sciences has leveraged the expertise and operational experience in regulatory compliance it has cultivated over many years to establish a transparent channel through which affluent Chinese clients can receive high-quality regenerative medicine services in Japan.
今後もJ&Sは、「中国と日本の間で高品質な再生医療サービスを届ける渡し守」としての役割を担い続け、確かな技術力を船に、厳格なコンプライアンス体制をオールに、国際的な最先端の再生医療リソースを中国の富裕層顧客の健康管理における信頼できる選択肢として提供していきます。